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要旨 
 
腸管出血性大腸菌 O157:H7（E. coli O157:H7）は、死者の発生を伴う食中毒
の原因菌として、Helicobacter pylori (H. pylori ) は、胃潰瘍、胃がんなどを誘
発する細菌としてよく知られており、これらの消化器感染症に対する有効な対応
策の確立が待たれている。 
そこで、乳牛で作製した免疫初乳抗体を用いてこれらの消化器感染症における
受動免疫の有効性を動物モデルで明らかにした。腸管感染症モデルでは、E. coli 
O157:H7 の産生するベロ毒素 2（VT2）に対する免疫初乳抗体を用いてマウスに
おける VT2 の吸収阻止効果を明らかにした。胃感染症モデルでは、H. pylori に
対する免疫初乳抗体及びその抗体と補体（新鮮ウシ血清）とを用いてスナネズミ
における除菌効果を実証した。これらの蛋白質分解酵素に強い抵抗性を有する免
疫初乳抗体は、乳牛でそれぞれ作製した。 
Ⅰ. 可溶性 VT2 に対する抗体測定が可能な間接蛍光抗体法（IFA）の開発 
IFA 用の VT2 感作ラテックスの調製及び乳牛への免疫原に用いた VT2 は、マ
ウス抗 VT2 モノクローナル抗体感作 Sepharose4B カラムを用いたアフィニティ
ークロマトグラフィーによって E. coli O157:H7 VT2 産生株の培養液から分離し
た。 
VT2 に対する免疫初乳抗体は、分娩 4 ヵ月前の乳牛へ毎週 1 回 VT2 を免疫し
て作製した。分娩 3 日後までの初乳を採取し、低速遠心による脱脂及びレンネッ
トによる脱カゼインを行って乳清を分離した。これを免疫初乳抗体として供試し
た。 
VT2 感作ラテックスは、粒径 6 μm の 2.5 %ラテックス粒子 0.5 ml へ 30 μg/ml
の VT2 1.0ml を感作して調製した。それを 20 %グリセリン、1 % 卵白アルブミ
ン（OVA）を含む食塩加リン酸緩衝液（PBS）に分散させ、この 5 μl を IFA 用
スライドガラスの well に塗抹して IFA スライドグラスを作製した。これに 1:2～
1:512 に希釈した免疫初乳抗体（10 μl / well）を加えて室温で１時間反応させた。
次に、至適濃度の FITC 標識抗ウシγグロブリン、IgG、IgA あるいは IgM 抗体
をそれぞれ 10 μl / well 反応させた。反応終了後、スライドガラスを 3.0M の塩化
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ナトリウムを含む PBS で洗浄することによって、非特異反応を完全に排除する
ことができた。なお、ラテックス粒子に自家蛍光は認めなかった。一般的な VT2
に対する抗体測定法であるベロ細胞を用いた中和試験では、免疫グロブリンクラ
ス別の抗体測定が不可能であったが、この IFA によってその問題が解決された。
この IFA で測定した免疫初乳抗体の抗体価は、免疫に用いた乳牛の血清抗体価の
約 4 倍高力価であった。免疫初乳抗体の IFA 価は、分娩直後に採取した初乳が最
も高い 1:512 を示し、分娩 3 日後までの初乳も 1:128～1:256 と比較的高力価を
示した。 
Ⅱ. マウスにおける免疫初乳抗体による VT2 の血中への吸収阻止作用 
マウスの血中に吸収された VT2 の濃度は、0.2 ng/ml まで測定可能な蛍光
ELISA によって測定した。マウス（146 匹）を用いて免疫初乳抗体による VT2
の血中への吸収阻止効果を検討した。 
吸収に至適な 477.8 ng/ml の VT2 0.3ml をゾンデを用いて投与し、その 1 時
間後から VT2 に対する免疫初乳抗体 0.3ml を 1 時間間隔で計 3 回投与したとこ
ろ、血中への VT2 の吸収は、わずか 0.3～2.6 ng/ml と微量であった。それに対
して、免疫初乳抗体の代わりに VT2 に対する抗体を含まない初乳乳清を投与した
対照群では、VT2 投与 12 時間後に 15.4 ± 5.0 ng/ml、16 時間後に 4.3 ± 1.6 
ng/ml まで上昇した。免疫初乳抗体を投与したマウスの VT2 濃度は、対照群に
比べて有意に低値を示した。これは、腸管内において免疫初乳抗体が VT2 と結合
して VT2 の毒素活性部位をブロックするとともに大きな免疫複合体を形成して
糞便中へ排泄されたために吸収量が少なかったと推察された。 
多量（955.6 ng/ml）の VT2 を投与した場合には、16 時間後にマウスの血中へ
わずか 8.2 ng/ml しか吸収されなかった。これは多量の VT2 によって腸管粘膜が
強く傷害され、吸収機能が低下したためと考えられた。 
Ⅲ. スナネズミにおける免疫初乳抗体による H. pylori の除菌効果 
H. pylori に対する免疫初乳抗体は、分娩 3 ヵ月前の乳牛へ毎週 1 回 H. pylori
を免疫して作製した。分娩後 3 日分の初乳を採取し、VT2 に対する免疫初乳抗体
と同様の方法で、乳清を分離した。この免疫初乳抗体は、H. pylori の菌体及び鞭
毛の両方に対する抗体活性を有していることを IFA で確認した上で、本実験に供
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試した。 
H. pylori の除菌に関する実験には、5~10 週齢のスナネズミ（101 匹）を用い
た。スナネズミへの H. pylori の接種は、ゾンデを用いて 0.1%重曹 0.3ml を投与
後、5×107CFU の H. pylori を 1 日に 1 回、2 日間接種し、2 週間後に ELISA に
よって H. pylori に対する血中の IgM 及び IgG 抗体価の上昇から感染の成立を確
認して本実験に用いた。なお、この ELISA での抗体価の上昇が、H. pylori 感染
成立の指標となることは、別な実験で確認済みである。 
除菌処置を施したスナネズミは、除菌処置終了 1 ヵ月後に安楽死させ、胃のホ
モジネート 10 μl をウマ血清加 BHI 培地に塗抹して 37℃、微好気環境下で 7 日
間培養した後に、H. pylori のコロニー形成の有無によって除菌効果を判定した。 
H. pylori を感染させたスナネズミへヒトの治療で最も一般的に用いられてい
るオメプラゾール、クラリスロマイシン及びアモキシシリンをヒトにおける用量
の約1.3倍量に相当する10mg/kg 及び約2倍量に相当する20mg/kgを1日2回、
7 日間経口投与した。その結果、H. pylori の除菌率は 10mg/kg 投与群で 92%
（11/12 例）、20 mg/kg 投与群では 100%（12/12 例）であった。 
免疫初乳抗体による除菌実験では、スナネズミへ 0.1 %重曹 0.3ml を投与して
胃内の pH を中性付近に調整した後に、0.5 ml の免疫初乳抗体を 1 日 2 回、1 ヵ
月間または 2 ヵ月間経口投与した。対照群へは、免疫初乳抗体の代わりに、H. 
pylori に対する抗体を含まない初乳乳清を同量投与した。その結果、H. pylori の
除菌率は、免疫初乳抗体 1 ヵ月間投与群で 83%（10/12 例）、2 ヵ月間投与群では、
薬剤 10 mg/kg 投与群と同じ、92%（11/12 例）であった。これらの対照群の除
菌率はいずれも 0%（0/6 例）であった。本実験に用いた免疫初乳抗体は、H. pylori
の菌体と鞭毛の両方に対する抗体活性を有していることから、抗体分子が H. 
pylori の菌体や鞭毛へ結合することによって H. pylori の運動性や定着の阻害に
加えて H. pylori との免疫複合体が形成されて排泄が促進され、除菌効果が発現
されたものと考えられた。 
免疫初乳抗体と補体とによる除菌実験では、スナネズミへ 0.1 %重曹 0.3 ml 投
与後、免疫初乳抗体及び補体をそれぞれ 0.5 ml、1 日 2 回、2~3 日間経口投与し
た。対照群のスナネズミへは免疫初乳抗体と 56℃、30 分間の加熱によって不活
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化した補体を実験群と同じ条件で投与した。その結果、免疫初乳抗体の 2 日間投
与群では 83 %（10/12 例）、3 日間投与群では 100 %（12/12 例）の除菌効果が認
められた。in vitro で、H. pylori へ免疫初乳抗体と補体とを作用させた場合に、
H. pylori が強く傷害（溶菌）される現象が確認されたことから、胃内においても、
in vitro と同様に、活性化された補体によって H. pylori の菌体が傷害された結果、
短期間で強い除菌効果が発現したと考えられた。これらの対照群では、いずれも
8%（1/12 例）の除菌率を示した。これは各除菌処置日における初回投与前に不
活化した補体の機能が時間の経過に伴って復活し、2 回目の抗体・不活化補体投
与時に補体が活性化されて H. pylori を傷害したためと考えられた。 
ヒトの H. pylori の除菌治療においては、薬剤耐性菌の出現及び薬剤に対する
過敏症患者への投与が問題となっている。それに対して、免疫初乳抗体あるいは
免疫初乳抗体と補体とを用いる方法は、牛乳アレルギーを有するヒト以外の患者
へ、耐性菌の問題が全くなく、反復投与ができる有用な H. pylori の感染予防法
あるいは除菌法として応用が可能と考えられた。ことに、胃内で補体を活性化さ
せる方法は、きわめて短期間で除菌が可能な画期的な手法になりうると考えられ
た。 
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Abstract 
A simple and novel assay method for determining colostral 
and serum against soluble verotxin 2 (VT2) titers by indirect 
fluorescent antibody (IFA) assay using latex sensitized with 
VT2 was devised. The latex particles did not auto-fluoresce, 
and nonspecific reactions disappeared after washing with 
phosphate buffered saline containing 3 M Nacl. The highest titer 
measured by neutralizing test was observed at 1 day after 
delivery. The highest titer for each immunoglobulin class 
measured by enzyme linked immunosorbent assay (ELISA) or IFA 
using latex sensitized with VT2 was also observed at 1 day after 
delivery. The changes in titer measured by each method showed 
similar patterns. Furthermore, the titers for IgG antibody were 
higher than those for IgM or IgA antibodies. Thus, the titers 
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of bovine immune colostral antibody and each immunoglobulin 
class could be measured by IFA using latex sensitized with VT2. 
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Introduction 
We have employed a neutralizing test using vero cells[1] 
to determine the neutralizing antibody titers of colostral and 
serum antibodies against vero toxin 2 (VT2) obtained from cows 
immunized with VT2. [2-4] However, this neutralizing test has some 
unresolved issues. For example, it is necessary to maintain vero 
cells for the neutralizing test, and the test itself requires 
at least 3 days to obtain the results. In addition, it is very 
difficult and/or impossible to determine the neutralizing 
antibody titers of each immunoglobulin class in the neutralizing 
test. Therefore, the protease resistance activity of each 
immunoglobulin class of colostral antibody recovered from the 
intestinal tract of beagle dogs was observed by enzyme-linked 
immunosorbent assay (ELISA). [4] 
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The authors have already reported a simple and novel 
indirect fluorescent antibody (IFA) technique using latex 
particles (latex) as a carrier for free soluble antigen to 
determine antibody titers. [4] This technique was considered to 
for application to various measurement methods. The aim of this 
study was to develop a novel assay method for determining 
colostral and serum antibodies against soluble VT2 and its 
immunoglobulin class titers by IFA using latex sensitized with 
VT2. 
 
Materials and Methods 
Escherichia coli O157:H7 
A strain of Escherichia coli O157:H7 producing only VT2 was used. 
[2] 
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 Quantification of proteins 
Purified VT2 was quantified by the Bradford method [23] using 
Coomassie brilliant blue G-250. Concentrations of colostral whey 
and each immunoglobulin class isolated from bovine colostrum 
were quantified using a Bio-Rad Protein Assay Kit (Bio-Rad 
Laboratories, Hercules, CA).  
 
Preparation of bovine colostral anti-VT2 antibody  
Three dairy cows were immunized with purified or crude VT2 
according to the method of Kuribayashi et al.[2] 
 
Latex particles 
Polybead polystyrene microspheres (2.5%(w/v)) (Polyscience, 
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Inc., Warrington, PA) having grain sizes of 6.0 μm were used. 
[4] 
 
Isolation of VT2 by affinity chromatography 
 Mouse anti-VT2 monoclonal antibody (Capricorn Products, LLC, 
Portland, ME, USA) was coupled to CNBr-activated Sepharose 4B 
(GE Healthcare UK Ltd., Little Chalfont, UK) as an 
immunoadsorbent and was then packed into column for affinity 
chromatography [21, 22]. Culture medium containing VT2 from E. coli 
O157:H7 was applied to the affinity column, which was washed 
with 0.01 M phosphate buffered saline (PBS) containing 0.14 M 
NaCl. After washing, VT2 was dissociated from the 
immunoadsorbent using 0.14 M glycine-HCl buffer (pH 2.3) and 
was immediately adjusted to pH 7.0 with Tris-HCl buffer (pH8.9). 
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 Neutralizing test 
Neutralizing test of colostral antibody titer was conducted 
according to the methods of Konowalchuk et al.[24] 
 
Preparation of VT2-sensitized latex for IFA 
The preparative procedure of VT2 sensitized latex was carried 
out according to the method of Kuribayashi et al.[4] Briefly, 
VT2 (30 g/ml) was dialyzed against 0.1 M borate buffer (pH 8.5) 
for 48 h and was used for sensitization to 0.5 ml of 2.5% latex. 
Latex was spread in PBS containing 20% glycerin, 1% ovalbumin 
(OVA) and 0.01% NaN3. Five microliters of latex coupled with VT2 
was placed onto the each well on the slide glass for fixation 
onto the slide glass for 12 h at room temperature. 
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 IFA technique 
IFA technique for bovine colostral antibody and each 
immunoglobulin class of colostral antibody was performed using 
a modification of the method reported by Killinger et al.[25] 
FITC-conjugated anti-bovine γ-globulin, IgG (Rockland 
Immunochemicals Inc., Gilbertsville, PA, USA), IgM (Bethyl 
Laboratories Inc., Montgomery, TX, USA) and IgA (Bethyl 
Laboratories Inc.) antibodies were diluted 2~512 times and then 
placed into each well to determine optimal dilutions. Slide 
glasses were washed with PBS containing 3 M NaCl and/or 0.14 
M NaCl for 15 min after the reaction. The IFA patterns were 
examined under a fluorescence microscope and the strength of 
fluorescence of VT2 sensitized latex was classified as 3+ ~ -. 
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IFA titers of antibodies were read as the maximum dilution at 
which a positive reaction was observed. 
 
Enzyme linked immunosorbent assay (ELISA)  
VT2 diluted with carbonate buffer (pH 9.6) was fixed to 
immunoplates for ELISA (Thermo Fisher Scientific Inc., Waltham, 
MA, USA) for 1 h and 1% ovalbumin dissolved in carbonate buffer 
(pH 9.6) was used to block unabsorbed sites. One hundred 
microliters of horseradish peroxide-labeled anti-bovine IgG, 
IgA or IgM was then added, and after 1 h, 2-fold diluted bovine 
colostral antibodies were added. Absorption was measured using 
a microplate reader equipped with 415 nm and 492 nm filters 
(Corona Electric Co., Ltd., Ibaragi, Japan). 
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Results 
IFA patterns 
The VT2-sensitized latex particles fixed onto the slide 
glass remained fixed during immersion, as described by 
Kuribayashi et al.[4] The latex particles did not show 
auto-fluorescence, and nonspecific reactions disappeared after 
washing with PBS containing 3 M NaCl (Figure 1). IFA patterns 
are shown in Figure 2. Titers of bovine colostral antibodies 
obtained from three cows measured by neutralizing test and IFA 
using VT2-sensitized latex particles and ELISA are shown Figure 
3.  
The highest titer measured by neutralizing test was observed 
at first milking after delivery. The titers of each 
immunoglobulin class measured by ELISA or IFA using 
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VT2-sensitized latex particles also showed the highest titer(s) 
in colostrum at first milking after delivery. The titers measured 
by each method decreased gradually with time. Furthermore, the 
decrease in titers of bovine colostral antibodies measured by 
each method was similar. The titers for IgG antibody measured 
by ELISA and IFA using VT2-sensitized latex particles were higher 
than those for IgM and IgA antibodies. 
 
Discussion 
We believe that it is possible to use IFA assay to determine 
soluble antibody titers using latex particles as a carrier of 
soluble antigen. [4] We therefore investigated whether antibody 
titers could be measured by IFA using VT2-sensitized latex 
particles. When washing with PBS, some antibody observed showed 
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weak nonspecific reactions. However, these nonspecific 
reactions disappeared after washing with PBS containing 3 M NaCl. 
This is likely due to the F/P ratio, which is 3.0~5.0 for 
FITC-conjugated antibodies 
The titers of bovine colostral antibodies measured by each method 
showed similar changes. Furthermore, the titers of each 
immunoglobulin class could be measure by IFA using 
VT2-sensitized latex particles. This technique was very useful, 
as it allows the titers of free soluble antigens to be easily 
and more rapidly determined. Furthermore, this technique can 
measure titers for each immunoglobulin class.  
We believed that it was possible to use IFA assay to measure 
free soluble antigen based on a preliminary study. [4] Titers for 
bovine colostral antibody against VT2 could be measured using 
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this method, but the most useful characteristic of this method 
is that the titer of each immunoglobulin class can be determined. 
In contrast, neutralizing tests using vero cells are unable to 
determine the titer of each immunoglobulin class. This method 
is thus considered to be very useful, and we plan to apply it 
to other free soluble antigens.  
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Figure and Table 
Figure 1: Nonspecific reactions of IFA disappeared after washing with 3 M NaCl.  
A, Washing by phosphate buffer saline containing 0.14M NaCl; B, Washing by phosphate buffer saline containing 3M 
NaCl. 
 29
3+ 2+ 
 
 
 
 
 
 
 
 
Negative 1+  
 
 
 
 
 
 
 
 
 
Figure 2: Appearance of latex under fluorescence microscope. 1+ 
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Figure 3. Changes in titers of each immunoglobulin class separated from bovine colostral antibody against verotoxin 2 
(Cow No.1). Days indicate time after delivery. A, IgG; B, IgM; C, IgA; D; γ-globulin. IFA: Antibody titers measured by IFA; 
EIA: Antibody titers measured by EIA; NT: Neutralization antibody titers measured using Vero cells. 
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Figure 3. Changes in titers of each immunoglobulin class separated from bovine colostral antibody against verotoxin 2 
(Cow No.2). Days indicate time after delivery. A, IgG; B, IgM; C, IgA; D; γ-globulin. IFA: Antibody titers measured by IFA; 
EIA: Antibody titers measured by EIA; NT: Neutralization antibody titers measured using Vero cells. 
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Figure 3. Changes in titers of each immunoglobulin class separated from bovine colostral antibody against verotoxin 2 
(Cow No.3). Days indicate time after delivery. A, IgG; B, IgM; C, IgA; D; γ-globulin. IFA: Antibody titers measured by IFA; 
EIA: Antibody titers measured by EIA; NT: Neutralization antibody titers measured using Vero cells. 
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Abstract 
Whether absorption of verotoxin (VT) 2 from the intestine in 
mice is inhibited by administration bovine immune colostral 
antibody to VT2 was investigated. Three-week-old mice were 
administered VT2 solution at 477.8 ng/ml or 955.6 ng/ml, and 
bovine immune colostral antibody against VT2 was then 
administered three times. Whey without antibody against VT2 was 
administered to control mice. Serum levels of VT2 were measured 
by fluorescence enzyme immunoassay. Serum levels of VT2 in mice 
administered VT2 solution at 477.8 ng/ml and bovine immune 
colostral antibody against VT2 scarcely changed. On the other 
hand, serum levels of VT2 in control mice increased and peaked 
at 12 hours after administration. Peak values were 15.4±5.04 
ng/ml. Furthermore, serum levels of VT2 at 12 and 16 hours in 
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control mice were significantly higher than in mice administered 
bovine colostral antibody against VT2. Serum levels of VT2 in 
mice administered antibody at 955.6 ng/ml showed no significant 
differences between repeated administration of bovine immune 
colostral antibody and controls. These results suggest that 
absorption of VT2 from the intestine was inhibited by repeated 
administration of bovine immune colostral antibody against VT2 
at early stages of E. coli O157:H7 infection, while VT2 in the 
intestine remained at low levels. 
 
Key waords: mice, absorption, intestine, VT2, bovine colostral 
antibody 
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Introduction 
Food poisoning caused by Escherichia coli (E. coli) O157:H7 
continues to occur in Japan (Koseki et al., 2011; Asano et al., 
2013). Treatment for this type of infection generally does not 
involve antibiotics (Carter et al., 1987; Karch, et al.,2005), 
as verotoxin 2 (VT2) released from E. coli O157:H7 killed by 
antibiotics induces serious complications, such as hemolytic 
uremic syndrome (HUS), thrombotic thrombocytopenic purpra (TPP) 
and brain damage (Ito et al., 1997; Wong et al., 2000; Baum et 
al., 2005). The authors have reported the neutralizing efficacy 
of bovine immune colostral antibody against VT2 in mice and 
beagle dogs (Kuribayashi et al. 2006 and 2009; Seita et al., 
2013). We compared serum levels of VT2 between co-administration 
of immune colostral antibody against VT2 and saline in mice 
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administered VT2 (Seita et al., 2013). Serum levels of VT2 were 
lower than in control mice after single administration of immune 
bovine colostral antibody. In particular, serum levels of VT 
at 8 and 12 hours after administration of VT2 were significantly 
lower than in control mice (Seita et al., 2013). However, the 
absorption of VT2 was not completely inhibited in this experiment. 
Thus, several administrations of bovine immune colostral 
antibody are necessary to inhibit the absorption of VT2 from 
the intestine. This study therefore investigated serum levels 
of VT2 in mice administered immune bovine colostral antibody 
repeatedly after administration of VT2. 
 
Materials and Methods 
Verotoxin 2 
 38
VT 2 was used supernatant of culture the E. coli O157:H7 
produced VT2 isolated from human. 
 
Mice 
Male SPF ICR mice (age, 3 weeks) were purchased from 
Charles River Inc. (Yokohama, Japan). Mice were kept in cages 
at a temperature of 23 ± 2°C, and a relative humidity of 55% 
± 10%, on a 12/12 dark (18:00-6:00)/light (6:00-18:00) cycle 
with the air exchanged 12 times or more per hour. Mongolian 
gerbils were fed MF (Oriental Yeast Co., Ltd., Tokyo, Japan), 
and were allowed free access to water. All experiments were 
approved by the Institutional Review Board of Azabu University 
and were conducted in accordance with the institute’s Animal 
Experimentation guidelines (Japanese Association for 
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Laboratory Animal Science, JALAS, 1987). 
 
Animal experiments 
First, the toxicity of VT2 administration was estimated. 
Four VT2 concentrations (955.6, 477.8, 318.5 or 238.9 ng/ml) 
were assessed, and four mice were administered VT2 at these 
concentrations. Mice were sacrificed at 16 hours after 
administration. Serum VT2 concentrations, hemoglobin and red 
blood cell counts were measured. Hemoglobin and red blood cell 
counts were measured by Celltac (Nihon Kohden Corporation, 
Tokyo, Japan). 
Mice were orally administered VT2 solution at 477.8 ng/ml 
or 955.6 ng/ml. Bovine colostral antibody against VT2 was given 
at 1 hour after administration, 3 times at 1-hour intervals 
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(bovine immune colostral antibody group). The control group was 
administered whey without antibody against VT2 instead of bovine 
colostral antibody against VT2. Blood was collected before and 
at 4, 8, 12, 16, 24, 36 and 48 hours after administration. Three 
mice were sacrificed for blood collection blood at each time 
point. Sera were obtained by centrifugation of blood at 1,610 
× g for 10 min. Sera were stored at -80°C until measurement.  
 
Measurement method for serum concentration of VT2 
Serum concentrations of VT2 were measured by fluorescence enzyme 
immunoassay according to the procedure of Seita et al. (Seita 
et al., 2013) 
 
Statistical analysis 
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Data are presented as means ± standard deviation for three mice 
at each time point. Statistical analysis of serum concentrations 
of VT2, hemoglobin and red blood cell count were performed by 
unpaired Student-t test. Differences were considered to be 
significant at p<0.05. 
 
Results  
Determination of VT2 doses 
Serum levels of VT2 were 8.2 ng/ml, 40.5 ng/ml, 2.9 ng/ml and 
2.3 ng/ml at 16 hours after administration of the various test 
concentrations (Figure 1). Mean hemoglobin and red blood cell 
counts are shown in Table 1. Hemoglobin in mice administered 
VT2 solution at 955.6 ng/ml was significantly lower when compared 
to mice administered other VT2 concentrations. Red blood cell 
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counts in mice administered VT2 solution at 955.6 ng/ml were 
also significantly lower when compared to mice administered VT2 
solutions at 477.8 or 318.5 ng/ml. 
 
Changes in VT2 levels in mice 
Serum levels of VT2 in mice administered VT2 solution at 955.6 
ng/ml and 477.8 ng/ml are shown in Figures 2 and 3, respectively. 
Serum levels of VT2 in mice administered VT2 solution at 955.6 
ng/ml did not show significant differences between repeated 
administration of bovine immune colostral antibody and controls. 
On the other hand, serum levels of VT2 in mice administered VT2 
solution at 477.8 ng/ml showed little changes in the repeated 
bovine immune colostral antibody administration group. Serum 
levels in control mice increased after administration of VT2 
 43
and peak levels were observed at 12 hours after administration 
(Figure 2). Peak levels were 15.4 ± 5.04 ng/ml. Serum levels 
in control mice at 12 and 16 hours were significantly higher 
than those in mice repeatedly administered bovine immune 
colostral antibody.  
 
Discussion 
VT2 derived from E. coli O157:H7 in the intestine is known to 
induced serious complications, including HUS and brain damage, 
in patients infected with E. coli O157:H7 (Pavia, et al., 1990; 
Clary et al., 2004; Phillips et al. 2005; Tarr et al., 2005). 
In infection models, mice showing intestinal bleeding died, but 
those not showing intestinal bleeding did not die (Kuribayashi 
et al., 2006; Seita et al., 2013). The cause of death was presumed 
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toxicity of VT2 absorbed from the intestine. The authors have 
reported that serum levels of VT2 continue to increase for 24 
hours in mice administered VT2 (Seita et al., 2013). Serum levels 
of VT2 in mice administered bovine immune colostral antibody 
against VT2 were lower than those in control mice (Seita et al., 
2013). However, absorption of VT2 was not fully inhibited by 
single administration of bovine immune colostral antibody. We 
presumed that serious complications were prevented by inhibiting 
absorption of VT2 from the intestine. Bovine immune colostral 
antibodies were thus administered repeatedly in this study.  
Serum levels at 16 hours after administration of VT2 were highest 
in mice administered VT2 solution at 477.8 ng/ml. On the other 
hand, hemoglobin and red blood cell counts in mice administered 
the VT2 solution at 955.6 ng/ml were significantly lower than 
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in mice administered VT2 solution at other concentrations. These 
results suggest that severe intestinal bleeding occurred and 
this interfered with intestinal function. Thus, the doses of 
VT2 used were 955.6 ng/ml and 477.8 ng/ml in order to evaluate 
the inhibition of VT2 absorption in mice.  
Serum concentrations of VT2 peaked at 12 hours after 
administration of VT2 and decreased in control mice administered 
VT2 solution at 477.8 ng/ml. In particular, serum levels of VT2 
at 12 and 16 hours in control mice were significantly higher 
than in mice administered bovine immune colostral antibody 
repeatedly. These results suggest that absorption of VT2 from 
the intestine was inhibited by three-time administration of 
bovine immune colostral antibody. However, serum levels of VT2 
were not significantly different between repeated 
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administration in the bovine colostral antibody group and the 
control group with VT2 administered at 955.6 ng/ml. It was 
assumed that VT2 was unable to be absorbed by the intestine to 
systemic circulation due to severe intestinal damage. The cause 
of death in mice with severe intestinal damage was considered 
to be bleeding.  
Kita et al. estimated the serum levels of Shiga toxin (Stx) 1 
in mice after inoculation with E. coli O157:H7 producing Stx 
1 and 2. Peak levels of 34.8±4.6 pg/ml were observed at 4 days 
after inoculation (Kita et al. 2000). Higher levels of VT2 were 
inhibited by repeated administration of bovine immune colostral 
antibody in this study. Furthermore, treatment of E. coli O157:H7 
infection with fosfomycin at early stages prevents progression 
to serious symptoms (Sawamura, et al. 1999;Takada et al. 2003). 
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Thus, adsorption of VT2 appeared to be inhibited by 
administration of bovine immune colostral antibody at early 
stages after infection with E. coli O157:H7, despite VT2 levels 
in intestine increasing from disruption of E. coli O157:H7 by 
antibiotics. Furthermore, serious complications such as HUS or 
encephalopathy caused by VT2 were prevented.  
Unfortunately, the mechanism of inhibition for absorption of 
VT2 by administration of bovine immune colostral antibody was 
not clarified in this study. Further study will therefore be 
necessary. 
In conclusion, the absorption of VT2 was inhibited by repeated 
administration of bovine immune colostral antibody against VT2 
in mice.   
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Figure 1 The serum levels at 16 hours after administered with different VT2 concentrations dosing solution to mice. 
Dosing solutions indicated VT2 concentration were following; 1:955.6 ng/ml, 2:477.8 ng/ml, 3:318.5 ng/ml, 4:238.9 ng/ml. 
Figure and Table  
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Figure 2  The serum levels of VT2 in mice administered VT2. The values at each time points represented mean  
standard deviation (n=5).  
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Figure 3 The serum levels of VT2 in mice administered VT2. The values at each time points represented mean  
standard deviation (n=5). *Value differs significantly from that of 3-week-old rats (p<0.05). 
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Table 1  Hemoglobin and Red blood cell count at 16 hours after administered with different VT2 concentrations dosing 
solution to mice. Each value represented mean  standard deviation (n=4). *Value differs significantly from mice 
administered with 477.8 of VT2 (p<0.05). 
Dosing levels of VT2 (ng/ml) Hemoglobin (g/dL) Red blood cell count (×106/L)
955.6 7.2±1.8* 386.3±102.3*
477.8 10.3±2.1 549.8±82.7
318.5 11.6±2.7 609.3±124.6
238.9 9.8±1.2 502.3±69.1
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 Introduction 
Helicobacter pylori (H. pylori) is a Gram-negative helical 
bacillus that was first isolated from the gastric mucosa in human 
patients by Warren and Marshall 1. H. pylori produces urease and 
sustains infection in the strongly acidic stomach environment 
by disassembling urea into ammonia and CO2 2, 3. Approximately half 
the population of Japan is considered to be infected with H. 
pylori 4, 5. As such, H. pylori infection is called the Japanese 
national disease. Chronic inflammation of gastric mucosa caused 
by H. pylori infection induces gastrointestinal diseases, such 
as gastric or duodenal ulcer 6, 7, gastric cancer 8, 9, and gastric 
MALT lymphoma 10. Other non-gastrointestinal diseases such as 
idiopathic thrombocytopenic purpura have also been reported. 11, 
12. 
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 Eradication therapy for patients with known H. pylori infection 
involves several antibiotics 13, 14, but three antibiotics, 
Omeprazole, Amoxicillin and Clarithromycin, tend to be used for 
treatment of patients infected with H. pylori 15. Treatment 
failure can occur with this antibiotic therapy, but the rate of 
bacterial eradication is 90% 16, 17. The risk of drug allergy and/or 
increased resistance of H. pylori to these antibiotics have also 
been reported 18. Therapies for bacterial eradication in 
experimental animals using Lactobacillus 19, green tea 20, 21, and 
cladosiphon fucoidan 22 has been reported. However, these 
therapies are not likely to completely eradicate H. pylori 
infection.  
The efficacy of bovine immune colostral antibody has already been 
investigated in human diseases. For example, bovine colostral 
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 antibody targeting rotavirus gastroenteritis is known to be 
particularly effective 23, 24. The authors have also reported that 
bovine immune colostral antibody has neutralizing efficacy 
against to verotoxin 2 derived from Escherichia coli O157:H7 in 
mice and beagle dogs 25. We prepared a bovine immune colostral 
antibody with activity against H. pylori by immunizing dairy cows 
before delivery. 
Mongolian gerbils are an experimental model of H. pylori 
infection 26. The effectiveness of immune colostral antibody and 
its antibody with bovine complement to eradicate H. pylori 
infection was thus investigated in Mongolian gerbils in this 
study. 
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 Materials and methods 
H. pylori  
An H. pylori strain isolated from human patients was donated by 
Professor Yasuhiro Koga, Tokai University School of Medicine, 
and was used in this study. H. pylori was cultured according to 
the procedure of Watanabe et al. 27 
 
Bovine immune colostral antibody 
A pregnant dairy cow (age, 8 years), 3 months prior to delivery, 
was used for preparation of immune colostral antibody against 
H. pylori. Colostrum was collected for 3–5 days after delivery. 
Skim milk was obtained by centrifuging colostrum in order to 
remove the fat. One hundred milligrams of RENNET (ICN Biomedicals, 
Aurora, OH) was added to 1 l of this skim milk. Colostrum was 
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 obtained from skim milk by centrifugation. 28 
 
Experimental animals 
One hundred and one Specific Pathogen Free (SPF) Mongolian 
gerbils (Japan SLC Inc., Shizuoka, Japan) aged 5-10 weeks were 
housed in an air-conditioned room with a 12-h light-dark cycle. 
They were fed normal diet and had free access to water until the 
start of experiment. All Mongolian gerbils were deprived of food 
beginning at 18 hours before experiments. All experiments 
conformed to Japanese regulations concerning animal care and use, 
as laid out in the Guidelines for Animal Experimentation 
(Japanese Association for Laboratory Animal Science, 1987), and 
were approved by the Institutional Animal Care and Use Committee 
of Azabu University. 
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Animal experiments 
Inoculation of H. pylori 
Mongolian gerbils were orally inoculated with 1 ml of BHI culture 
fluid suspension of 5.0×107 H. pylori after administration of 
0.1% sodium carbonate in order to raise internal stomach pH. This 
was performed once per day over a period of two days. Sera were 
collected after 2 weeks of inoculation and IgG and IgM titers 
against H. pylori were measured by enzyme linked immunosorbent 
assay (ELISA). Mongolian gerbils confirmed to be infected with 
H. pylori by increased antibody titers were used for subsequent 
H. pylori eradication experiments.  
 
Administration of antibody, complement and medications 
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 Mongolian gerbils were orally administered with 0.3 ml of 0.1% 
sodium bicarbonate solution to increase the pH in the stomach 
at 10 minutes before administration of colostral antibody. 
Subsequently, Mongolian gerbils were orally administered with 
0.5 ml of colostral antibody against H. pylori. Whey not including 
antibody against H. pylori was administered to control Mongolian 
gerbils instead of colostral antibody against H. pylori. 
Colostral antibody against H. pylori or whey was administered 
to Mongolian gerbils twice a day for one month or two months. 
Mongolian gerbils were orally administered Omeprazole, a proton 
pump inhibitor, and the antibiotics Clarithromycin and 
Amoxicillin at a dose of 10 mg/kg or 20 mg/kg body weight twice 
a day for 7 days in order to compare the efficacies between 
standard therapies for humans. These drug substances were 
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 dissolved in 0.5% methylcellulose 400 (Wako Pure Chemical Inc., 
Osaka, Japan).  
In order to study the bactericidal effects of complement, 
Mongolian gerbils were orally administered 0.5 ml of colostral 
antibody and complement twice a day for 2-3 days. Bovine serum 
was incubated at 56ºC for 30 minutes in order to inactivate 
complement. Then, inactivated complement was administered to 
control Mongolian gerbils.  
 
Culture from the stomach 
One month after finishing administration experiments, stomachs 
from euthanized gerbils were extracted and homogenized with a 
9-fold volume of PBS. Homogenates were diluted and 10 μl was 
cultured. H. pylori was cultured according to the procedure of 
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 Makino et al. 29 
 
Result 
IFA using colostral antibody, fluorescence was seen on both the 
membrane and flagella of H. pylori (Fig. 1). Animal experiments 
were performed using this colostral antibody. 
Bacterial eradication rates in the groups administered drug at 
10 mg/kg and 20 mg/kg were 92% (11/12) and 100% (12/12), 
respectively. Eradication rates in the groups administered 
colostral antibody for one month and two months were 83% (10/12) 
and 92% (11/12), respectively. On the other hand, the eradication 
rate was 0% (0/6) in the group administered whey without colostral 
antibody, and H. pylori was detected in the stomach. In Mongolian 
gerbils administered complement and colostral antibody, in 
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 groups administered medication twice a day or for three days, 
the eradication rates were 100% (12/12) and H. pylori was not 
detected in the stomach. On the other hand, in groups administered 
medication twice a day for two days, the eradication rate was 
83% (10/12) and, the rate was 17% (1/6) in the control group given 
inactivated complement. 
Colonies grown from the gastric specimens were subjected to 
urease test, and the results confirmed that all colonies were 
H. pylori. These results were subsequently confirmed by CLO test. 
 
Discussion 
H. pylori induces gastritis, ulcers and gastric cancer 8, 9 and 
it is recommended to eliminate the bacterium. Treatment with 
antibiotics is the currently standard therapy to eliminate 
 70
 bacteria in various countries, including Japan 30. However, 
treatment with antibiotics involves risks such as appearance of 
side effects, drug allergy and bacterial resistance. Moreover, 
some cases of difficult to eliminate bacteria have been reported. 
The number of patients infected H. pylori is estimated to be 
thirty million in Japan; thus, H. pylori infection in Japan cannot 
be overlooked.   
It is known that colostral whey contains a rich S-IgA, which is 
resistant to protease enzymes and is often present at levels 
similar to IgG. The authors have reported improved survival rates 
in mice treated with verotoxin or inoculated with Escherichia 
coli O157:H7 after administration of bovine immune colostral 
antibodies against verotoxin 25, 28. We estimated the eradication 
of H. pylori in Mongolian gerbils by administration of bovine 
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 immune colostral antibody in this study. Fluorescence was 
observed on both the membrane and flagella using IFA, and 
colostral antibody obstructed adhesion.  
Disinfection rates were evaluated at one month after completing 
administration of bovine immune colostral antibody or both 
antibiotics and PPI in this study. Disinfection of H. pylori in 
humans was evaluated at one month after the end of treatment with 
drug therapy in order to confirm that H. pylori did not increase 
after the end of drug therapy. Elimination of H. pylori in 
Mongolian gerbils was evaluated after the administration period.  
The elimination rates by administration of antibiotics and PPI 
were similar to those in previous reports. These elimination 
rates were similar to those with administration of bovine 
colostral antibody for 1 or 2 months. Thus, H. pylori disinfection 
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 by bovine colostral antibody without antibiotics was 
satisfactory. However, the treatment periods are longer than 
with standard drug therapy. Therefore, we evaluated the 
synergistic efficacy of bovine immune colostral antibody and 
complement. 
Administration of bovine immune colostral antibody and 
complement for three days resulted in complete eradication of 
H. pylori in Mongolian gerbils. The bovine immune colostral 
antibody was also able to avoid allergic responses and induction 
of drug resistance. The disinfection efficacy for H. pylori by 
bovine immune colostral antibody indicates its utility as a novel 
treatment for H. pylori infection.   
Sterilization with continuous oral treatment for 1 and 2 months 
with immunized colostral antibodies can give a successful 
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 eradication rate of 83% and 92%, respectively, and antibody alone 
has an eradication rate of 92% with 2 months of continuous 
administration. However, when complement and colostral 
antibodies are administered both at the same time, twice a day 
for 3 days, 100% eradication was achieved. It is known that 
complement has a strong bactericidal action, but bacterial 
growth is not stopped with antibody alone or inactive complement.  
Sterilization with bovine immunized colostral antibodies and 
complement showed a high eradication rate in experimental 
animals. In contrast to antibiotics, there is a lower risk of 
creating resistant strains, and it is expected to be effective 
against previously reported resistant strains. The appearance 
of resistant bacteria is causing problems in the eradication 
treatment of H. Pylori. Bovine immune colostral antibody or 
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 complement with immune colostral antibody can be utilized on a 
daily basis, except in those who are allergic to milk. Furthermore, 
the method of combining complement and immune colostral antibody 
is useful because it can eradicate H. pylori in a very short period 
of time. Therefore, this combination treatment is a good 
alternative to antibiotics. 
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 Table 1  Eradication rate of H. pylori infected Mongolian gerbils treated with three medications 
 
Agent Dose(s) (mg/kg)
OPZ, CAM, AMPC 10, 10, 10 92% (11/12)
OPZ, CAM, AMPC 20, 20,20 100% (12/12)
7 days
Medications
Eradication rate
Duration of
administration
 
 
Figure and Table 
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 Table 2  Eradication rate of H. pylori infected Mongolian gerbils treated with bovine immune colostral antibodies 
 
Duration of
administration
2 months 92% (11/12)
1 months 83% (10/12)
2 months 0% (0/6)
1 months 0% (0/6)
Eradication rate
Bovine immune
colostral antibody
administration group
Control colostral
administration group
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 Table 3  Eradication rate of H. pylori infected Mongolian gerbils treated with bovine immune colostral antibodies 
 
Duration of
administration
3 days 100% (12/12)
2 days 83% (10/12）
1 day 40% (2/5)
3 days 17% (1/6)
2 days 17% (1/6)
Bovine immune colostral antibody
and complement administration
group
Bovine immune colostral antibody
and inhibited complement
administration group
Eradication rate
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Figure 1  Specificity of bovine immune colostral antibody against H. pylori using the IFA method. Flagellum and 
somatic shows fluorescence 
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